CDMRP receives annual appropriations that are disease or condition-specific. Hereditary Ataxia has been included on the list of eligible diseases within the Peer-Reviewed Medical Research Program since 2023. All organizations, including foreign organizations, foreign public entities, and international organizations, are eligible to apply for funding.
The following mechanisms provide funding opportunities for Hereditary Ataxia research:
- Clinical Trial Award: Supports the rapid implementation of clinical trials of novel interventions.
- Discovery Award: Supports the exploration of a highly innovative new concept or untested theory.
- Focused Program Award: Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal/question.
- Investigator-Initiated Research Award: Supports research that will make an original and important contribution to the field of research or patient care in the Topic Area(s) of interest.
- Technology/Therapeutic Development Award: Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, and/or quality of life.
